Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 10 kg~* Age ≥ 4 years~* Diagnosis of Rett syndrome based on consensus clinical criteria and patients with MECP2 duplications will not be eligible.~* Has at least 10 episodes of breathing dysrhythmia, defined by episodes ≥10 seconds of breath holding (apnea), per hour during cardiorespiratory monitoring~* Ability to take study medication provided either as capsules or combined with food/drink.~* Patient is cooperative, willing to complete all aspects of the study, and capable of doing so with assistance of a caregiver.~Exclusion Criteria:~* Meets any of the diagnostic exclusion criteria for Rett syndrome, Typical (Neul et al, 2010);~* Patient is participating in a clinical trial with another investigational drug~* Hypersensitivity to sarizotan or other 5-HT1a agonists;~* Current clinically significant (as determined by Investigator) cardiovascular, respiratory (e.g. severe asthma), gastrointestinal, renal, hepatic, hematologic or other medical disorders, in addition to those directly related to the patient's Rett syndrome;~* QTcF interval on the ECG is greater than 450 msec.~* Surgery planned during the study (except for insertion of gastrostomy tube);~* Severe diabetes mellitus or fatty acid oxidation disorder.~* Ophthalmologic history including any of the following conditions: albino patients, family history of hereditary retinal disease, retinitis pigmentosa, any active retinopathy or severe diabetic retinopathy.~* Females who are pregnant, breastfeeding, or of childbearing potential and not using a hormonal contraceptive.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarizotan low dose (Type: EXPERIMENTAL): 2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 5 mg bid (≥13 years of age and weighing ≥25 kg)
- Sarizotan high dose (Type: EXPERIMENTAL): 5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 10 mg bid (≥13 years of age and weighing ≥25 kg)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo bid for 24 wks DB age 4 and above

Based on this trial design, predict the completion outcome and termination type (if applicable).